PRTA · Prothena Corp Public Ltd Co
Market Cap
$478.97M
Shares
51.34M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$9.68M
-92.8%
FY2025
Net Income
-$244.09M
-99.6%
FY2025
Operating Margin
-2216.44%
-2102.1pp
FY2025
Diluted EPS
-$4.53
-99.6%
FY2025
Operating Cash Flow
-$163.58M
-9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $54.53M | $9.68M | $135.16M | $91.37M | $53.91M | $200.58M | $853K | $814K | $955K | $27.52M | $1.06M | $1.61M | $50.85M | $676K | $2.66M | — | |
| $10.97M | $14.14M | $25.82M | $31.01M | $6.35M | $42K | $1.37M | $8.2M | $2.69M | -$142K | $556K | $196K | $79K | — | — | — | |
| $64.95M | $134.85M | $222.52M | $220.57M | $135.56M | $82.28M | $74.88M | $50.84M | $101.18M | $134.55M | $119.53M | $58.44M | $38.45M | $26.05M | $34.14M | $24.17M | |
| $49.45M | $59.39M | $67.2M | $61.84M | $49.9M | $46.32M | $38.7M | $35.74M | $42.48M | $48.23M | $41.06M | $23.11M | $19.05M | $15.05M | $9.93M | $5.58M | |
| $828K | $895K | $893K | $928K | $744K | $1.12M | $1.51M | $1.56M | $3.22M | $3.07M | $2.43M | $806K | $743K | $660K | $468K | $391K | |
| — | — | — | — | — | — | — | -$61K | $14.72M | — | — | — | — | — | — | — | |
| $110.04M | $224.32M | $289.72M | $282.41M | $185.46M | $128.6M | $113.59M | $86.51M | $159.81M | $182.77M | $160.59M | $81.54M | $57.5M | $41.1M | $44.07M | $29.75M | |
| -$55.51M | -$214.64M | -$154.56M | -$191.04M | -$131.56M | $71.98M | -$112.73M | -$85.7M | -$158.86M | -$155.25M | -$159.54M | -$79.94M | -$6.65M | -$40.43M | -$41.41M | -$29.24M | |
| — | -2216.44% | -114.36% | -209.08% | -244.05% | 35.88% | -13216.18% | -10527.89% | -16634.03% | -564.17% | -15121.8% | -4974.3% | -13.07% | -5980.33% | -1557.94% | — | |
| -$54.68M | -$213.75M | -$153.67M | -$190.11M | -$130.81M | $73.09M | -$111.22M | -$84.13M | -$155.64M | -$152.19M | -$157.11M | -$79.13M | -$5.91M | -$39.77M | -$40.94M | -$28.85M | |
| $11.16M | $13.81M | $25.63M | $30.56M | $5.95M | -$54K | $1.31M | $8.4M | $2.74M | -$2.35M | $571K | $26K | $310K | -$154K | $5000 | $0 | |
| -$44.35M | -$200.83M | -$128.93M | -$160.48M | -$125.61M | $71.92M | -$111.43M | -$77.3M | -$156.12M | -$157.6M | -$158.96M | -$79.91M | -$6.34M | -$40.58M | -$41.41M | -$29.24M | |
| -$358K | $43.26M | -$6.62M | -$13.45M | -$8.66M | $4.95M | -$283K | $379K | -$470K | -$4.37M | $1.14M | $701K | $811K | $415K | $6000 | $426K | |
| -$43.99M | -$244.09M | -$122.31M | -$147.03M | -$116.95M | $66.98M | -$111.14M | -$77.68M | -$155.65M | -$153.24M | -$160.11M | -$80.61M | -$7.15M | -$41M | -$41.41M | -$29.67M | |
| — | -2520.57% | -90.49% | -160.91% | -216.95% | 33.39% | -13029.78% | -9542.63% | -16297.91% | -556.84% | -15176.11% | -5016.3% | -14.06% | -6064.5% | -1557.98% | — | |
| USD/shares | -$0.82 | -$4.53 | -$2.27 | -$2.76 | -$2.47 | $1.51 | -$2.78 | -$1.95 | — | — | — | — | — | — | — | — |
| USD/shares | -$0.83 | -$4.53 | -$2.27 | -$2.76 | -$2.47 | $1.38 | -$2.78 | -$1.95 | — | — | — | — | — | — | — | — |
| shares | — | 53.83M | 53.77M | 53.22M | 47.37M | 44.23M | 39.92M | 39.88M | 39.56M | 37.65M | 34.35M | 30.33M | 24.67M | 18.62M | 14.59M | 14.5M |
| shares | — | 53.83M | 53.77M | 53.22M | 47.37M | 48.46M | 39.92M | 39.88M | 39.56M | 37.65M | 34.35M | 30.33M | 24.67M | 18.62M | 14.59M | 14.5M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.00×
EV/EBIT
—
Peer median 9.78×
P/E (TTM)
—
Peer median 12.42×
Peer medians compare against the 311 similar-size Biotechnology companies (of 513 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Collaboration | $9,634,000 | $135,107,000 | $91,320,000 | $13,855,000 | $139,833,000 | $564,000 | $814,000 | $955,000 |
| License | $50,000 | $50,000 | $50,000 | $40,050,000 | $60,744,000 | $289,000 | $0 | $0 |
Key facts
CIK
1559053
CUSIP
G72800108
13F (30d)
155 filings
153 filers
Visit website
Investor relations